Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
about
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progressionAndrogen deprivation therapy as backbone therapy in the management of prostate cancerPredictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapyA national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.
P2860
Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Detectable prostate-specific a ...... ults from the SEARCH database.
@en
type
label
Detectable prostate-specific a ...... ults from the SEARCH database.
@en
prefLabel
Detectable prostate-specific a ...... ults from the SEARCH database.
@en
P2093
P2860
P1433
P1476
Detectable prostate-specific a ...... ults from the SEARCH database.
@en
P2093
Christopher J Kane
Christopher J Keto
Christopher L Amling
Joseph C Presti
Stephen J Freedland
William J Aronson
P2860
P304
P356
10.1016/J.EURURO.2012.11.052
P407
P577
2012-12-06T00:00:00Z